Drug Profile
DS 2248
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Inc
- Class Antineoplastics
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-small cell lung cancer; Solid tumours
Most Recent Events
- 02 Mar 2015 Daiichi Sankyo terminates phase I trial in Non-small cell lung cancer and Solid tumours in USA (NCT01288430)
- 31 Jul 2014 Discontinued - Phase-I for Non-small cell lung cancer in USA (PO)
- 31 Jul 2014 Discontinued - Phase-I for Solid tumours in USA (PO)